Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top

18-09-2024 | Diabetes Therapy | News

EASD 2024

Effect of diabetes medication on neuropsychiatric disorders

Login to get access

MedNet.nl: In a real-world evidence study of over 5 million people with type 2 diabetes, SGLT2 inhibitors appear to provide more and better protection for neuropsychiatric health than GLP-1 receptor agonists and metformin. In a late breaking session at the 60th EASD Congress, the results of this study were presented.

Related topics

EASD 2024 rotated-square
Type 2 Diabetes rotated-square
Diabetes and Psychosocial Issues rotated-square
Sodium Glucose Co-Transporter 2 Inhibitors rotated-square
Incretin Mimetics rotated-square
Metformin rotated-square
Alzheimer's Disease rotated-square
Schizophrenia rotated-square
Depressive Disorders rotated-square
Endocrinology rotated-square

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits